AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05032664 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Wait-list control, no intervention for 3 weeks, then provide home-based aromatherapy
Study NCT04753346 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary Fitness Level
Description: Cardiopulmonary Exercise Test
Study NCT05265793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab Combined With Apatinib
Description: After signing the informed consent, the selected patients received Camrelizumab combined with Apatinib. Treatment until disease progression and intolerable adverse reactions occur
Study NCT05857007 — intervention group
Intervention type: DEVICE
Intervention: Libre 2.0 CGM in patients taking subcutaneous insulin with concomitant high dose glucocorticoids
Description: Ten patients with hyperglycemia or/and diabetes in the neuro ICU requires subcutaneous insulin with concomitant high dose glucocorticoids will wear Libre 2.0 CGM for either 14 days or their stay in the neuro ICU
Study NCT05438706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide
Description: Chidamide, an HDAC inhibitor
Study NCT05438706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. The drug is also being investigated as a treatment for various other malignancies, including B cell lymphoma, oesophageal squamous cell carcinoma, gastric/gastroesophageal junction cancer, hepatocellular carcinoma, nasopharyngeal cancer and non-squamous, non-small cell lung cancer.
Study NCT06095050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embolization
Description: Superselective arterial embolization of hyperemic vasculature in the symptomatic shoulder (utilizing the IDE approved device: Lipiodol) followed by structured physical therapy sessions.
Study NCT05438706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin \[diammine(1,1-cyclobutanedicarboxylato)platinum(II)\] is one of the most promising second generation platinum compounds. Its greater chemical stability in comparison with cisplatin accounts for its lower reactivity with nucleophilic sites of DNA.
Study NCT05438706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) and approved for treatment of various malignancies. Hereditary genetic variants may affect a drug's pharmacokinetics or pharmacodynamics and account for differences in treatment response and adverse events among patients.
Study NCT04494529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 12 mg betamethasone + placebo
Description: After the first intramuscular injection of 12 mg of betamethasone, participants randomized to the Placebo Comparator group will receive 1 intramuscular injection of placebo.
Study NCT04494529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 24 mg betamethasone
Description: After the first intramuscular injection of 12 mg of betamethasone, participants randomized to the Active Comparator group will receive the standard 2nd intramuscular injection of 12 mg of betamethasone.
Study NCT04753346 — intervention group
Intervention type: OTHER
Intervention: Cognitive Assessment
Description: Montreal Cognitive Assessment
Study NCT06095050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Subjects will participate in structured physical therapy consisting of 3 months of eccentric strength training. This twelve-week program will consist of 4 PT sessions at week 0, week 4, week 8, and week 12.
Study NCT06095050 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Subjects will participate in structured physical therapy consisting of 3 months of eccentric strength training. This twelve-week program will consist of 4 PT sessions at week 0, week 4, week 8, and week 12.
Study NCT05997602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-159
Description: 5mg/m² (Maximum dose does not exceed 8mg, the recommended oral dose for adults), orally, once daily, continuously for 28 days per cycle.
Study NCT06790355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multi-cancer early detection
Description: Blood collection for multi-cancer early detection（MCED）, followed by clinical diagnosis based on the results of MCED and standard-of-care screening
Study NCT06790446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric training group (ECC)
Description: The first, preparatory phase, lasts two weeks, aiming at making the participant familiar with the principles of eccentric training. Participants first experience the muscle recruitment patterns (during two sessions), then are prepared to induce protective response from the plantar flexors, conditioning these muscles for higher subsequent eccentric intensities.~The aim of the second, training phase per se, which lasts six weeks, is to induce muscular and neurological adaptations through a steady increase in work intensity to stimulate muscle plasticity until the end of the program - varying volume, load and speed.~Perceived exertion is quantified using Borg's scale (expected rating between 3 and 6) to ensure sufficient work intensity and prevent excessive fatigue. Musculoskeletal pain is assessed before and after each session through a Visual Analog Scale (0-10). Verbal encouragements and advising on correct exercise execution are provided by the therapist along each session.
Study NCT06790446 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: The participant visits a physiotherapist depending on the prescription, as in current practice
Study NCT06791512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody
Description: Participants in the experimental group will receive the neoadjuvant therapy regimen of mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody. And the first five doses received the neoadjuvant therapy regimen of mFOLFOX6 (intravenous oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2, and 5-fluorouracil 2400 mg/m2 continuous pumping for 48 hours) combined with sintilimab (200 mg, intravenous) and Bevacizumab (5 mg/kg, intravenous), and the sixth dose received the same regimen of mFOLFOX6 and PD-1 monoclonal antibody but not plus bevacizumab, in order to allow sufficient withdrawal time of Bevacizumab for surgery.
Study NCT06791512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: Participants in the control group will receive the neoadjuvant therapy regimen of mFOLFOX6 (intravenous oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2, and 5-fluorouracil 2400 mg/m2 continuous pumping for 48 hours) alone.
Study NCT06791967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based walking program
Description: The home-based walking intervention involves five walking sessions per week over 12 weeks, with a target of 3,000 additional steps per session beyond daily activities. In the first week, participants in the experimental group will wear a smart wristband upon waking to record their average daily steps, which will guide their walking goals. By the 7th week, participants are expected to achieve at least 3,000 extra steps per session, completed in 30 continuous minutes. The wristband, synced via Bluetooth to its companion app, can store up to one month of walking data. Weekly phone follow-ups will record participants' daily step counts. No additional cloud uploads of personal data are required.
Study NCT06790667 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Low Level Laser Therapy
Description: Participants in this arm will receive Low-Level Laser Therapy (LLLT) using a Gallium Aluminum Arsenide (GaAlAs) semiconductor diode laser. The treatment involves a wavelength range of 650-808 nm with a power output of 775 mW. The therapy is administered by exposing tender points around the temporomandibular joint (TMJ) to the laser for 2 minutes per session. Each participant will receive treatment on alternate days (three sessions per week) over the course of three weeks. The goal is to assess the effectiveness of LLLT in reducing pain and improving mouth opening in patients with myofascial pain associated with Temporomandibular Disorders (TMD).
Study NCT06790667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Pulsed Electrical Stimulation (Device: Nu Eyne M02)
Description: Participants in this arm will undergo Transcutaneous Electrical Nerve Stimulation (TENS), utilizing a four-electrode unit. The device will be set to deliver electrical impulses at a frequency of 150 Hz with a pulse width of 200 µs. Electrodes will be placed over the cutaneous region between the TMJ and coronoid process to stimulate the trigeminal and facial nerves. Each treatment session will last 15 minutes and occur on alternate days, three times a week for three weeks. This therapy aims to provide pain relief and improve jaw function for patients suffering from myofascial pain associated with TMD.
Study NCT05854797 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Walking
Description: Adhering to FITT method, normal walking will be performed 5 days a week (frequency) to ensure optimal results. Speed (intensity) for normal will be 3.5 mph. The pulse rate of participants will be monitored through treadmill monitor. The duration (time) of walk each day will be 30 minutes.~Measurement of body fat percentage, hypertension, diabetes, and level of happiness (at the beginning and ending of twelve weeks)
Study NCT05854797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brisk Walking
Description: Adhering to FITT method, brisk walking will be performed 5 days a week (frequency) to ensure optimal results. Speed (intensity) for normal will be 4.5 mph. The pulse rate of participants will be monitored through treadmill monitor. The duration (time) of walk each day will be 30 minutes.~Measurement of body fat percentage, hypertension, diabetes, and level of happiness (at the beginning and ending of twelve weeks)
Study NCT06442566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine Patch
Description: Buprenorphine patch dosing will be individualized based on each participant's current morphine-equivalent dose (per package insert/recommendations; between 5mcg and 20mcg per hour). Dosage based on baseline MEQ (\<30 MEQ = 5mcg/hr patch, 30-80 MEQ =10-15mcg/hour patch; >80 MEQ = 20mcg/hour patch), which will remain on for 7 days (Phase Ia Days 1-7), as tolerated
Study NCT06442566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Patch
Description: Buprenorphine patch dosing will be individualized based on each participant's current morphine-equivalent dose (per package insert/recommendations; between 5mcg and 20mcg per hour). Dosage based on baseline MEQ (\<30 MEQ = 5mcg/hr patch, 30-80 MEQ =10-15mcg/hour patch; >80 MEQ = 20mcg/hour patch), which will remain on for 7 days (Phase Ia Days 1-7), as tolerated
Study NCT06442566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: double-blinded randomization to placebo or transdermal buprenorphine
Study NCT06442566 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: double-blinded randomization to REAL intermittent theta burst (iTBS) rTMS
Study NCT06442566 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation (TMS)
Description: double-blinded randomization to SHAM intermittent theta burst (iTBS) rTMS
Study NCT06071390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animated- assisted video
Description: For the experimental group, 15 minutes prior to the endoscopy, the researcher provided insight into the procedure by showing them a 3-minute animated video titled Endocan. This video, crafted by Köse in 2019 for his doctoral dissertation, offers a succinct overview of the endoscopy procedure.
Study NCT05698108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization (IASTM)
Description: Tools designed for soft tissue mobilization
Study NCT05698108 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Moist Hot pack, Ultrasound, Deep Friction Massage, Stretching and Strengthening Exercises.
Study NCT05211661 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory Muscle Testing
Description: Comprehensive assessment of respiratory muscle function. Comprehensive assessment of respiratory muscle function to the point of its invasive assessment with recordings of twitch transdiaphragmatic pressure in response to magnetic phrenic nerve stimulation and stimulation of the lower thoracic nerve roots.
Study NCT05387213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team Huddles
Description: Brief multidisciplinary meeting occurring twice a week for staff working at a LTC home led by a Nurse Practitioner. Huddles focused on discussing resident-care and staff-wellbeing.
Study NCT05185284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 400 mg, lyophilizate for preparation of concentrate for solution for infusion
Study NCT05185284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favipiravir
Description: 200 mg coated tablets
Study NCT05185284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: 100 mg, lyophilizate for preparation of concentrate for solution for infusion
Study NCT06790589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine Oral Tablet [Synthroid]
Description: Round, colour coded, scored tablet debossed with SYNTHROID on one side and potency on the other side.
Study NCT06790589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine Oral Tablet [Synthroid]
Description: Round, colour coded, scored tablet debossed with SYNTHROID on one side and potency on the other side.
Study NCT05410782 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Power Prenatal for Sperm
Description: A prenatal vitamin complex that includes numerous ingredients aim at improving sperm quality (ingredients: https://birdandbe.com/the-power-prenatal-for-sperm)
Study NCT04679389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered orally or enterally
Study NCT04679389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: administered orally or enterally
Study NCT04535505 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Detection pathogenic pertussis by cross primer constant temperature amplification (CPA) and drug resistant genes of erythromycin by CRISPR technology
Description: This is an observational study and there are no interventions. The purpose of the study is to compare the accuracy （including sensitivity and specificity）of the new CPA platform based on CRISPR technology detection method and the gold standard in detecting pertussis patients.
Study NCT01089166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT01089166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT04592848 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Four Questionnaires in French will be sent to participants :~* 1 questionnaire about sexual and urinary symptoms before and after the surgery ;~* 1 validated questionnaire Female Sexual Function Index to assess sexual function over the past 4 weeks ;~* 1 validated questionnaire Body Image Scale to assess body image during the past week ;~* 1 validated questionnaire Stoma Quality of Life, only for patients with incontinent urostomy.~If the questionnaires are not returned 15 days after sending, a follow-up phone call will be made by one of the investigators.~The data collection will include both the answers to the questionnaires and the patients' computerized medical data:~* Pathology responsible for the urological disorders and date of onset of the disorders~* Date and Type of surgery performed~* Patient's age at the time of surgery~* Post-operative complications within one month of surgery
Study NCT05308160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10Mg Tab
Description: This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease. This is a principal investigator initiate study. This study is supported by Liver Disease Prevention \& Treatment Research Foundation. Dapagliflozin will be provided free of charge by AstraZeneca.
Study NCT06791031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inclisiran
Description: Patients randomized to the inclisiran early intensified therapy arm will receive initial treatment with inclisiran sodium 300 mg (equivalent to inclisiran 284 mg) on moderate-intensity statin therapy (i.e., atorvastatin: 20 mg; rosuvastatin: 10 mg) during hospitalization for the index ACS (administered within 24 hours after randomization), regardless of baseline LDL-C levels and whether on stable statin treatment or not. Subsequent doses will be administered by healthcare professionals at the month 3 and month 9 study visits and documented in the patient's medical history, without dose adjustment throughout the study. The study only provided inclisiran as PCSK9 inhibitors in the inclisiran early arm. The baseline types and regiments of lipid-lowering drugs other than PCSK9 inhibitors were maintained throughout the study period in both experimental and control group.
Study NCT05308160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease. This is a principal investigator initiate study. This study is supported by Liver Disease Prevention \& Treatment Research Foundation. Dapagliflozin will be provided free of charge by AstraZeneca.
Study NCT04564703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: IBERDOMIDE (CC220) IN MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
Study NCT03176498 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord mesenchymal stem cell
Description: Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
Study NCT03176498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin Enteric-coated Tablets & Atorvastatin Calcium
Description: Aspirin Enteric-coated Tablets, 0.1g/d by mouth; Atorvastatin Calcium, 20mg/d by mouth.
Study NCT03176498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Enteric-coated Tablets & Atorvastatin Calcium
Description: Aspirin Enteric-coated Tablets, 0.1g/d by mouth; Atorvastatin Calcium, 20mg/d by mouth.
Study NCT04664062 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medication Assisted Treatment
Description: All subjects will undergo MAT induction with buprenorphine. Participants will be randomized to the behavioral aspects of induction, specifically comparing office induction vs home vs synchronous telehealth induction.
Study NCT05391698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (BPT)
Description: The parent training consists of 8 weekly group sessions where parents are trained on behavior modification techniques, optimal parental practices as well as techniques for the enhancement of their children's cognitive deficits.
Study NCT05391698 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Child Training (iVR + CBT)
Description: The child training program is comprised of 16 individualized weekly sessions. It utilizes the potentials of immersive virtual reality (iVR) technology for the training of focused and sustained attention and combines practices based on cognitive-behavioral approach for children's training on behavioral and emotional self-regulation skills.
Study NCT05437926 — intervention group
Intervention type: DEVICE
Intervention: Arrhythmia Analysis Software (software) which runs on a mobile application (Huawei Phone) and uses input from a wearable device (smart watch or smart band).
Description: Subjects with or without cardiac arrhythmias and of light skin tone (melanin index \<150) or dark skin tone (melanin index >350). Subjects will be divided based on their heart rhythm in three groups: approximately 1/3 with normal sinus rhythm, 1/3 with atrial fibrillation and 1/3 with premature beats
Study NCT05429320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local ablative therapy
Description: In part I, 33 patients with metastatic NSCLC with: a) NR-VAF but b) without radiographic progression of disease, will be treated with LAT. In Part II of the study, patients will be randomized to standard of care (continuation of systemic therapy) vs. LAT to all sites of disease
Study NCT05429320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection to assess for ctDNA
Description: Participants will undergo ctDNA collection in conjunction with their standard of care therapy.
Study NCT05429320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood collection to assess for ctDNA
Description: Participants will undergo ctDNA collection in conjunction with their standard of care therapy.
Study NCT04848012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-titrating non-invasive ventilation
Description: A non-invasive ventilator designed to auto-adjust the expiratory positive airway pressure according to expiratory flow limitation, measured using the forced oscillation technique.